

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 February 2021 (04.02.2021)



(10) International Publication Number
WO 2021/019473 A1

(51) International Patent Classification:

C07K 14/74 (2006.01) C12N 15/12 (2006.01)
A61K 38/17 (2006.01) G01N 33/567 (2006.01)
A61P 35/00 (2006.01) C12N 5/07 (2010.01)

(21) International Application Number:

PCT/IB2020/057173

(22) International Filing Date:

29 July 2020 (29.07.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/880,501 30 July 2019 (30.07.2019) US
63/029,114 22 May 2020 (22.05.2020) US

(71) Applicant: **UNIVERSITY HEALTH NETWORK**
[CA/CA]; 101 College Street, Unit 150, Toronto, Ontario
M5G-1L7 (CA).


(72) Inventors: **HIRANO, Naoto**; 101 College Street, Unit 150,
Toronto, Ontario M5G-1L7 (CA). **SUGATA, Kenji**; 101
College Street, Unit 150, Toronto, Ontario M5G-1L7 (CA).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: MHC CLASS II MOLECULES AND METHODS OF USE THEREOF

FIG. 1D



(57) Abstract: The present disclosure is directed to HLA class II molecules having a higher affinity for CD4 than naturally occurring HLA class II molecules. In certain aspects, the HLA class II molecule comprises a DQ beta chain having (i) an amino acid other than leucine at a position corresponding to amino acid residue 114 of SEQ ID NO: 1, (ii) an amino acid other than valine at a position corresponding to amino acid residue 143 of SEQ ID NO: 1, (iii) or both (i) and (ii). Certain aspects of the present disclosure are directed to nucleic acid molecules encoding the HLA class II molecules, vectors comprising the nucleic acid molecule, cells comprising the same, and methods of use thereof.

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE*